Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston
Tübingen, Germany, May 11, 2022 Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being… Read More »